Here we can show for the first time that the efficacy of PMD-026 and RSK inhibition in general extends to malignant melanoma cells with MAPK pathway hyperactivation, including not only the BRAFMut subgroup irrespective of the response to MAPK pathway inhibitors but also melanomas with RASMut or NF-1LOF, for which no effective targeted treatment options have been yet available. The gene discussed is RPS6KA1; the disease is melanoma.